Last reviewed · How we verify
NCT05989425
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Phase 2 trial testing surufatinib in Differentiated Thyroid Cancer in 32 participants. Currently enrolling.
4 August 2026
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 4 August 2023 |
| Primary completion | 4 August 2026 |
| Estimated completion | 4 August 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- surufatinib — full drug profile →
Conditions studied
- Differentiated Thyroid Cancer — all drugs for Differentiated Thyroid Cancer →
Sponsor
Fudan University
Who can join
Adults 18 to 75, any sex, with Differentiated Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Locally advanced thyroid cancer has a wide range of surgery, large trauma and high local recurrence rate. It is one of the main causes of death in patients with thyroid cancer. Therefore, more effective treatments are urgently needed. This study is designed to evaluate the efficacy and safety of the Surufatinib for Locally Advanced Thyroid Cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05989425
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of surufatinib
Trials testing the same drug.
- NCT07279532 — Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edit · Phase 2 · not yet recruiting
- NCT05832892 — Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic · Phase 1, PHASE2 · unknown
- NCT04372394 — A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects · Phase 1 · completed
Other recruiting trials for Differentiated Thyroid Cancer
Currently open trials in the same condition.
- NCT07436455 — F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer · NA · recruiting
- NCT06458036 — Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) · Phase 2 · recruiting
- NCT05783323 — Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer · Phase 2 · recruiting
- NCT05599139 — Iodine Uptake After a Low Iodine Diet · NA · recruiting
- NCT05538130 — A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced So · Phase 1 · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05989425 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 14 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05989425.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing